Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ginseng “country of harvest” labeling

This article was originally published in The Tan Sheet

Executive Summary

Ginseng marketers are required to disclose the country where the herbal ingredient was harvested or face a fine under a bill introduced by Sen. Russ Feingold (D-Wisc.) May 20. The "Ginseng Harvest Labeling Act of 2004" (S 2452) is intended to protect Wisconsin farmers, who produce 97% of the country's ginseng, from smugglers who attempt to label their foreign products as "Wisconsin grown," Feingold notes in floor comments. The Senator says his incorporation of suggestions from the Ginseng Board of Wisconsin into the bill make it stronger than legislation he previously introduced on the issue (1"The Tan Sheet" Oct. 23, 2000, In Brief)...

You may also be interested in...



Ginseng labeling

"Country of origin" statement on all products containing the herbal would be required under bill recently introduced by Sen. Feingold (D-Wisc.). Noting the Badger State produces 97% of the ginseng grown in the U.S., Feingold says in his floor comments that smugglers have been switching higher-quality, "lower pesticide and chemical content" product from Wisconsin with cheaper imports. "Chinese ginseng has a retail value of about $5-$6 per pound, while Wisconsin ginseng is valued at roughly $16-$20 per pound," he notes. The bill, S 3005, referred to the Commerce Committee and likely to be taken up next session, stipulates retailers must indicate where their ginseng is grown or face a fine

Drug Pricing Policies Attached To Surprise Medical Billing Legislation

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.

Topics

UsernamePublicRestriction

Register

PS096880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel